SCHEMBL2381166

SCHEMBL2381166

CN(C)CCCNc1nccc2c(-c3ccc4cc(NC(=O)c5ccsc5)ccc4c3)cccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TERT O14746 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ RAD52 P43351 1/20 0.39
▸ AXL P30530 1/20 0.38
▸ KCNK3 O14649 1/20 0.38
▸ KCNK9 Q9NPC2 1/20 0.38
▸ FYN P06241 1/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ ROCK2 O75116 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ ROCK1 Q13464 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ SYK P43405 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ HTR1D P28221 1/20 0.36
▸ HTR1B P28222 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12245704 0.95 KCNK3 (0.39) AXLKCNK3KCNK9ROCK2ROCK1
SCHEMBL14639945 0.89 KCNK3 (0.40) AXLKCNK3KCNK9MAPK14KMT2A
SCHEMBL2381797 0.86 KMT2A (0.41) KDM4ERAD52AXLALDH1A1MAPT
SCHEMBL2379747 0.81 HDAC2 (0.44) KDM4EAXLCYP3A4CYP2C9ALDH1A1
SCHEMBL14605010 0.79 RAD52 (0.37) TERTKDM4ERAD52ALDH1A1SYK
SCHEMBL14605011 0.79 RAD52 (0.37) TERTKDM4ERAD52ALDH1A1SYK
SCHEMBL2380299 0.71 ABL1 (0.52) KCNK3KCNK9ROCK2ROCK1KDR
SCHEMBL2381779 0.70 GLA (0.49) KDM4ECYP3A4CYP2D6ALDH1A1MAPT
SCHEMBL2383216 0.70 ABL1 (0.48) KCNK3KCNK9MAPTMAPK14
SCHEMBL2381767 0.68 KCNK3 (0.47) KCNK3KCNK9MAPK14KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017601-B2 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2011-09-13 — — US disclosed
US-8017601-B2 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2011-09-13 — — US disclosed
US-8017601-B2 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2011-09-13 — — US disclosed
US-20070054903-A1 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2007-03-08 — — US disclosed
US-20070054903-A1 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2007-03-08 — — US disclosed
US-20070054903-A1 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2007-03-08 — — US disclosed
WO-2007005668-A2 BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER AMGEN INC. (US) 2007-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054903-A1 Bis-aryl kinase inhibitors and method HGF, MET, BLK TERT 820/4885KDM4E 2585/4885RAD52 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback